nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—Methimazole—Graves' disease	0.232	0.308	CbGbCtD
Irbesartan—CYP2C9—Methimazole—Graves' disease	0.209	0.277	CbGbCtD
Irbesartan—CYP2D6—Methimazole—Graves' disease	0.191	0.254	CbGbCtD
Irbesartan—CYP3A4—Methimazole—Graves' disease	0.121	0.161	CbGbCtD
Irbesartan—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0115	0.0981	CcSEcCtD
Irbesartan—Aplastic anaemia—Methimazole—Graves' disease	0.00624	0.0531	CcSEcCtD
Irbesartan—Vasculitis—Propylthiouracil—Graves' disease	0.00579	0.0493	CcSEcCtD
Irbesartan—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00531	0.0452	CcSEcCtD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00393	0.0423	CbGpPWpGaD
Irbesartan—Jaundice—Methimazole—Graves' disease	0.00363	0.0308	CcSEcCtD
Irbesartan—JUN—eye—Graves' disease	0.00352	0.0971	CbGeAlD
Irbesartan—Agranulocytosis—Methimazole—Graves' disease	0.00347	0.0295	CcSEcCtD
Irbesartan—JUN—connective tissue—Graves' disease	0.00339	0.0935	CbGeAlD
Irbesartan—Hepatitis—Methimazole—Graves' disease	0.00334	0.0284	CcSEcCtD
Irbesartan—AGTR1—Arf6 signaling events—TSHR—Graves' disease	0.00324	0.0349	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00308	0.0332	CbGpPWpGaD
Irbesartan—Jaundice—Propylthiouracil—Graves' disease	0.00308	0.0262	CcSEcCtD
Irbesartan—Agranulocytosis—Propylthiouracil—Graves' disease	0.00295	0.0251	CcSEcCtD
Irbesartan—EDNRA—pituitary gland—Graves' disease	0.00286	0.079	CbGeAlD
Irbesartan—EDNRA—adipose tissue—Graves' disease	0.00285	0.0787	CbGeAlD
Irbesartan—Hepatitis—Propylthiouracil—Graves' disease	0.00284	0.0242	CcSEcCtD
Irbesartan—Vertigo—Methimazole—Graves' disease	0.00261	0.0222	CcSEcCtD
Irbesartan—JUN—pituitary gland—Graves' disease	0.00261	0.0721	CbGeAlD
Irbesartan—Leukopenia—Methimazole—Graves' disease	0.0026	0.0221	CcSEcCtD
Irbesartan—JUN—adipose tissue—Graves' disease	0.0026	0.0718	CbGeAlD
Irbesartan—AGTR1—Arf6 trafficking events—TSHR—Graves' disease	0.00256	0.0276	CbGpPWpGaD
Irbesartan—AGTR1—connective tissue—Graves' disease	0.00255	0.0704	CbGeAlD
Irbesartan—Arthralgia—Methimazole—Graves' disease	0.00247	0.0211	CcSEcCtD
Irbesartan—Myalgia—Methimazole—Graves' disease	0.00247	0.0211	CcSEcCtD
Irbesartan—EDNRA—thyroid gland—Graves' disease	0.00247	0.0681	CbGeAlD
Irbesartan—Dysgeusia—Propylthiouracil—Graves' disease	0.00242	0.0206	CcSEcCtD
Irbesartan—Oedema—Methimazole—Graves' disease	0.00237	0.0202	CcSEcCtD
Irbesartan—Thrombocytopenia—Methimazole—Graves' disease	0.00232	0.0198	CcSEcCtD
Irbesartan—EDNRA—Peptide GPCRs—TSHR—Graves' disease	0.00227	0.0244	CbGpPWpGaD
Irbesartan—JUN—thyroid gland—Graves' disease	0.00225	0.0621	CbGeAlD
Irbesartan—Vertigo—Propylthiouracil—Graves' disease	0.00222	0.0189	CcSEcCtD
Irbesartan—Leukopenia—Propylthiouracil—Graves' disease	0.00221	0.0188	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00216	0.0184	CcSEcCtD
Irbesartan—Paraesthesia—Methimazole—Graves' disease	0.00213	0.0181	CcSEcCtD
Irbesartan—Somnolence—Methimazole—Graves' disease	0.00211	0.0179	CcSEcCtD
Irbesartan—Arthralgia—Propylthiouracil—Graves' disease	0.0021	0.0179	CcSEcCtD
Irbesartan—Myalgia—Propylthiouracil—Graves' disease	0.0021	0.0179	CcSEcCtD
Irbesartan—JUN—Apoptosis—TNFRSF25—Graves' disease	0.00209	0.0225	CbGpPWpGaD
Irbesartan—Dyspepsia—Methimazole—Graves' disease	0.00209	0.0178	CcSEcCtD
Irbesartan—Oedema—Propylthiouracil—Graves' disease	0.00202	0.0172	CcSEcCtD
Irbesartan—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00198	0.0168	CcSEcCtD
Irbesartan—AGTR1—pituitary gland—Graves' disease	0.00197	0.0543	CbGeAlD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TNFRSF25—Graves' disease	0.00196	0.0211	CbGpPWpGaD
Irbesartan—AGTR1—adipose tissue—Graves' disease	0.00196	0.054	CbGeAlD
Irbesartan—Urticaria—Methimazole—Graves' disease	0.00188	0.016	CcSEcCtD
Irbesartan—Body temperature increased—Methimazole—Graves' disease	0.00188	0.016	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00184	0.0156	CcSEcCtD
Irbesartan—Paraesthesia—Propylthiouracil—Graves' disease	0.00181	0.0154	CcSEcCtD
Irbesartan—Somnolence—Propylthiouracil—Graves' disease	0.00179	0.0153	CcSEcCtD
Irbesartan—AGTR1—Peptide GPCRs—TSHR—Graves' disease	0.00178	0.0192	CbGpPWpGaD
Irbesartan—Dyspepsia—Propylthiouracil—Graves' disease	0.00178	0.0151	CcSEcCtD
Irbesartan—JUN—CD40/CD40L signaling—CD40—Graves' disease	0.00171	0.0184	CbGpPWpGaD
Irbesartan—AGTR1—thyroid gland—Graves' disease	0.00169	0.0468	CbGeAlD
Irbesartan—Pruritus—Methimazole—Graves' disease	0.00168	0.0143	CcSEcCtD
Irbesartan—Urticaria—Propylthiouracil—Graves' disease	0.0016	0.0136	CcSEcCtD
Irbesartan—Body temperature increased—Propylthiouracil—Graves' disease	0.00159	0.0136	CcSEcCtD
Irbesartan—Vomiting—Methimazole—Graves' disease	0.00151	0.0128	CcSEcCtD
Irbesartan—Rash—Methimazole—Graves' disease	0.0015	0.0127	CcSEcCtD
Irbesartan—Dermatitis—Methimazole—Graves' disease	0.00149	0.0127	CcSEcCtD
Irbesartan—Headache—Methimazole—Graves' disease	0.00149	0.0126	CcSEcCtD
Irbesartan—JUN—TSH signaling pathway—TSHR—Graves' disease	0.00146	0.0157	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.00145	0.0156	CbGpPWpGaD
Irbesartan—Pruritus—Propylthiouracil—Graves' disease	0.00143	0.0121	CcSEcCtD
Irbesartan—Nausea—Methimazole—Graves' disease	0.00141	0.012	CcSEcCtD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.00139	0.015	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IL2RA—Graves' disease	0.00135	0.0146	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.0013	0.014	CbGpPWpGaD
Irbesartan—Vomiting—Propylthiouracil—Graves' disease	0.00128	0.0109	CcSEcCtD
Irbesartan—Rash—Propylthiouracil—Graves' disease	0.00127	0.0108	CcSEcCtD
Irbesartan—Dermatitis—Propylthiouracil—Graves' disease	0.00127	0.0108	CcSEcCtD
Irbesartan—Headache—Propylthiouracil—Graves' disease	0.00126	0.0108	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—HLA-E—Graves' disease	0.00125	0.0135	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—HLA-DRB1—Graves' disease	0.00122	0.0132	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—CD40—Graves' disease	0.00122	0.0131	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—CTLA4—Graves' disease	0.0012	0.013	CbGpPWpGaD
Irbesartan—Nausea—Propylthiouracil—Graves' disease	0.0012	0.0102	CcSEcCtD
Irbesartan—PTGS1—connective tissue—Graves' disease	0.00112	0.031	CbGeAlD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—FASLG—Graves' disease	0.00108	0.0116	CbGpPWpGaD
Irbesartan—CYP2C8—pituitary gland—Graves' disease	0.00107	0.0294	CbGeAlD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—FAS—Graves' disease	0.00104	0.0112	CbGpPWpGaD
Irbesartan—JUN—IL-2 Signaling Pathway—IL2RA—Graves' disease	0.00103	0.0111	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000991	0.0107	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000938	0.0101	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.000917	0.00987	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000899	0.00967	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IFNG—Graves' disease	0.000892	0.00961	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-B—Graves' disease	0.00089	0.00958	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—FASLG—Graves' disease	0.00087	0.00937	CbGpPWpGaD
Irbesartan—PTGS1—pituitary gland—Graves' disease	0.000864	0.0239	CbGeAlD
Irbesartan—JUN—IL12 signaling mediated by STAT4—CD4—Graves' disease	0.000862	0.00928	CbGpPWpGaD
Irbesartan—PTGS1—adipose tissue—Graves' disease	0.000861	0.0238	CbGeAlD
Irbesartan—CYP1A2—thyroid gland—Graves' disease	0.00086	0.0237	CbGeAlD
Irbesartan—JUN—IL2-mediated signaling events—IL2RA—Graves' disease	0.000845	0.0091	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—FAS—Graves' disease	0.000839	0.00903	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL2RA—Graves' disease	0.000834	0.00898	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-A—Graves' disease	0.000825	0.00888	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.000799	0.0086	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000786	0.00846	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000754	0.00811	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.000751	0.00808	CbGpPWpGaD
Irbesartan—PTGS1—thyroid gland—Graves' disease	0.000745	0.0206	CbGeAlD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.000744	0.00801	CbGpPWpGaD
Irbesartan—JUN—RANKL/RANK Signaling Pathway—ICAM1—Graves' disease	0.000722	0.00777	CbGpPWpGaD
Irbesartan—JUN—IL1-mediated signaling events—IL1B—Graves' disease	0.00072	0.00775	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.00072	0.00775	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000716	0.0077	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000712	0.00766	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000701	0.00754	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.000689	0.00742	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—HLA-A—Graves' disease	0.000679	0.00731	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.000665	0.00716	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000634	0.00682	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD8A—Graves' disease	0.000623	0.00671	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—FASLG—Graves' disease	0.000619	0.00666	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—FAS—Graves' disease	0.000597	0.00643	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000593	0.00638	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.000581	0.00625	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000581	0.00625	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—FASLG—Graves' disease	0.000581	0.00625	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000565	0.00609	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—FAS—Graves' disease	0.000565	0.00608	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000562	0.00604	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—FAS—Graves' disease	0.00056	0.00603	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000558	0.006	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—IFNG—Graves' disease	0.000558	0.006	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IFNG—Graves' disease	0.00055	0.00593	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—TSHR—Graves' disease	0.000545	0.00587	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.000541	0.00582	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—ICAM1—Graves' disease	0.000525	0.00565	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IFNG—Graves' disease	0.000519	0.00559	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000519	0.00559	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—Graves' disease	0.000514	0.00553	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000508	0.00547	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—FASLG—Graves' disease	0.000503	0.00541	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL1B—Graves' disease	0.000491	0.00529	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—IL1B—Graves' disease	0.00049	0.00528	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000475	0.00511	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—IFNG—Graves' disease	0.000464	0.00499	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000462	0.00498	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IFNG—Graves' disease	0.000453	0.00488	CbGpPWpGaD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—Graves' disease	0.000441	0.00475	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—Graves' disease	0.000441	0.00475	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—TSHR—Graves' disease	0.000428	0.0046	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.00041	0.00442	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IFNG—Graves' disease	0.000399	0.0043	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—FAS—Graves' disease	0.000397	0.00427	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000384	0.00413	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000363	0.00391	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—Graves' disease	0.000361	0.00388	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD4—Graves' disease	0.000358	0.00385	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TNF—Graves' disease	0.000356	0.00384	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—FASLG—Graves' disease	0.000356	0.00383	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CXCL10—Graves' disease	0.000352	0.00379	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000346	0.00373	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—FAS—Graves' disease	0.000343	0.00369	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL1B—Graves' disease	0.000331	0.00356	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IFNG—Graves' disease	0.000328	0.00353	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000321	0.00345	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000309	0.00333	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TSHR—Graves' disease	0.000308	0.00331	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	0.000307	0.00331	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000299	0.00322	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—FAS—Graves' disease	0.000297	0.0032	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL1B—Graves' disease	0.000292	0.00314	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000289	0.00311	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TSHR—Graves' disease	0.00028	0.00301	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCL10—Graves' disease	0.000276	0.00297	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000263	0.00283	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TNF—Graves' disease	0.000253	0.00273	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IFIH1—Graves' disease	0.000242	0.0026	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TSHR—Graves' disease	0.000242	0.0026	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—Graves' disease	0.000236	0.00254	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	0.000235	0.00253	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000233	0.00251	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GC—Graves' disease	0.000229	0.00246	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TSHR—Graves' disease	0.000219	0.00236	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	0.000217	0.00234	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000214	0.0023	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000213	0.00229	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—IL1B—Graves' disease	0.000201	0.00216	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL10—Graves' disease	0.000199	0.00214	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000199	0.00214	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-E—Graves' disease	0.00019	0.00205	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000187	0.00201	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCL10—Graves' disease	0.000181	0.00195	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000177	0.00191	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—B3GNT2—Graves' disease	0.000173	0.00186	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	0.00017	0.00183	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000169	0.00182	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TSHR—Graves' disease	0.000165	0.00178	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL10—Graves' disease	0.000156	0.00168	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000154	0.00166	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2RA—Graves' disease	0.000152	0.00164	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000152	0.00164	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—Graves' disease	0.000146	0.00157	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL10—Graves' disease	0.000142	0.00153	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFIH1—Graves' disease	0.000141	0.00152	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2RA—Graves' disease	0.000138	0.00149	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-B—Graves' disease	0.000136	0.00146	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000131	0.00141	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00013	0.0014	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSHR—Graves' disease	0.00013	0.0014	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GC—Graves' disease	0.000129	0.00139	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000129	0.00138	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000129	0.00138	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2RA—Graves' disease	0.000119	0.00128	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-E—Graves' disease	0.000111	0.00119	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2RA—Graves' disease	0.000108	0.00117	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40—Graves' disease	0.000108	0.00117	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL10—Graves' disease	0.000107	0.00115	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTLA4—Graves' disease	0.000107	0.00115	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—B3GNT2—Graves' disease	9.76e-05	0.00105	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSHR—Graves' disease	9.69e-05	0.00104	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-DQB1—Graves' disease	8.79e-05	0.000946	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL10—Graves' disease	8.38e-05	0.000902	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GC—Graves' disease	8.32e-05	0.000895	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—Graves' disease	8.21e-05	0.000884	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2RA—Graves' disease	8.16e-05	0.000878	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—Graves' disease	8.09e-05	0.000871	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-B—Graves' disease	7.9e-05	0.00085	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2RA—Graves' disease	7.4e-05	0.000796	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-A—Graves' disease	7.32e-05	0.000787	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GC—Graves' disease	6.83e-05	0.000735	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GC—Graves' disease	6.77e-05	0.000729	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-DRB1—Graves' disease	6.68e-05	0.000719	CbGpPWpGaD
Irbesartan—JUN—Immune System—ICAM1—Graves' disease	6.42e-05	0.000691	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2RA—Graves' disease	6.4e-05	0.000689	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—B3GNT2—Graves' disease	6.3e-05	0.000678	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL10—Graves' disease	6.26e-05	0.000674	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GC—Graves' disease	5.78e-05	0.000623	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—B3GNT2—Graves' disease	5.17e-05	0.000557	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—B3GNT2—Graves' disease	5.13e-05	0.000552	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—Graves' disease	4.88e-05	0.000525	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2RA—Graves' disease	4.78e-05	0.000515	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—Graves' disease	4.71e-05	0.000507	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GC—Graves' disease	4.46e-05	0.000481	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—B3GNT2—Graves' disease	4.38e-05	0.000472	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—Graves' disease	4.35e-05	0.000469	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—B3GNT2—Graves' disease	3.38e-05	0.000364	CbGpPWpGaD
